**Supplementary Table 1. Characteristics of studies that met our inclusion criteria.**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Author** | **Age in years** | **Gender, male/total** | **Cirrhotic or not** | **Naïve or experienced** | **Viral load** |
| TDF vs. ENT | Batirel *et al*.28 | TDF: 43.3±12.9ENT: 42.0±11.2 | TDF: 59/90ENT: 82/108 | NA | Naïve | TDF (×103 IU/mL): 191613±198.6ENT (×103 IU/m:): 220199±101.3l |
| Cai *et al*.19 | TDF: 30.796±8.782ENT: 30.956±8.411 | TDF: 119/157ENT: 121/158 | NA | Naïve | TDF (log10 IU/mL): 7.57±0.929ENT (log10 IU/mL): 7.697±0.975 |
| Centeno *et al*.34 | TDF: 50.15±16.17ENT: 49.22±15.26 | TDF: 25/32ENT: 23/32 | NA | NA | TDF (copies/mL): 1,127.4 (19-2,463,121.4)ENT (copies/mL): 29,311.4 (376.2-4,660,135.2) |
| Ceylan *et al*.29 | TDF: 45 (22-66)ENT: 41 (20-73) | TDF: 37/66ENT: 28/51 | NA | NA | TDF (×103 IU/mL): 5500 (0.14-1110000)ENT (×103 IU/mL): 117 (0.17-7130000) |
| Ha *et al*.30 | TDF: 43.2±10.7ENT: 45.8±12.5 | TDF: 66/114ENT: 276/443 | NA | Naïve | TDF (log10 IU/mL): 6.15±1.55 ENT (log10 IU/mL): 6.12±1.52 |
| Jayakumar *et al*.31 | TDF: 34±9.60ENT: 42.15±17.11 | TDF: 19/19ENT: 16/20 | NA | NA | TDF (log10 copies/mL): 5.91 (4.0-10.1)ENT(log10 copies/mL): 7.69(4.0-8.5)  |
| Kayaaslan *et al*.32 | TDF: 42 (18-71)ENT: 43 (18-81) | TDF: 48/86ENT: 118/166 | NA | Naïve | NA |
| Koike *et al*.22 | TDF: 45.4±9.23ENT: 46.1±9.68 | TDF: 68/109ENT: 40/56 | NA | Naïve | TDF (log10 copies/mL): 7.00±1.498ENT (log10 copies/mL): 7.19±1.313 |
| Kwon *et al*.33 | TDF: 47.79±9.39ENT: 50.60±11.66 | TDF: 6/39ENT: 226/40 | NA | Naïve | TDF (×103 IU/mL): 6.38±1.21TDF (×103 IU/mL): 6.24±1.24 |
| Ozaras *et al*.36 | NA | TDF: 72/121ENT: 92/130 | NA | Previously untreated CHB | TDF (×1010 IU/mL): 3.17±32ENT (×108 IU/mL): 5.09±22.5 |
| Park *et al*.37 | TDF: 45.5±11.9ENT: 47.0±12.0 | TDF: 67/105ENT: 64/105 | NA | Naïve | TDF (log10 IU/mL): 6.56±1.33ENT (log10 IU/mL): 6.66±1.26  |
| Riveiro-Barciela *et al*.38 | TDF: 50±13ENT: 50±13 | TDF: 305/424ENT: 139/187 | NA | NA | TDF (log IU/mL): 3.8±2.3 ENT (log IU/mL): 4.9±2.4 |
| Pereira *et al*.42 | TDF: 47.7±11.2ENT: 55.8±12.1 | TDF: 216/336ENT: 133/165 | TDF: 2/336ENT: 6/165 | NA | TDF (IU/mL): 27,998 (5,240-1,001,600)ENT (IU/mL): 82,850 (1,670-5,584,400) |
| Shi *et al*.39 | TDF: 33.7±4.6ENT: 35.1±4.5 | TDF: 23/30ENT: 49/66 | NA | NA | TDF (log10 IU/mL): 7.25±0.83ENT (log10 IU/mL): 7.33±0.79 |
| Sriprayoon *et al*.26 | TDF: 41.2±11.6ENT: 41.6±11.5 | TDF: 113/200ENT: 121/200 | TDF: 29/200ENT: 31/200 | Naïve | hepatitis B e antigen-positiveTDF (log10 IU/mL): 7.0±1.4ENT (log10 IU/mL): 7.1±1.5NegativeTDF (log10 IU/mL): 5.0±1.3ENT (log10 IU/mL): 4.9±1.3 |
| Yim *et al*.27 | TDF: 47±11ENT: 51±11 | TDF: 15/22ENT: 15/23 | TDF: 4/45ENT: 2/23 | Naïve | TDF (log10 IU/mL): 2.71±0.74ENT (log10 IU/mL): 2.69±0.72 |
| Yu *et al*.41 | TDF: 48.8±13.0ENT: 51.7±10.3 | TDF: 22/49ENT: 33/58 | NA | Naïve | TDF (log10 copies/mL): 7.05±1.33ENT (log10 copies/mL): 6.98±1.55 |
| TAF vs. TDF | Agarwal *et al*.15 | TAF: 40 (18-80)TDF: 41 (18-72) | TAF: 544/866TDF: 275/432 | NA | NA | TDF (log10 IU/mL): 7.0 (1.4-9.9) ENT (log10 IU/mL): 7.0 (1.8-9.9) |
| Buti *et al*.16 | TAF: 45±12TDF: 48±10 | TAF: 173/185TDF: 86/140 | NA | NA | TDF (log10 IU/mL): 5.7±1.3ENT (log10 IU/mL): 5.8±1.3 |
| Buti *et al*.17 | NA | NA | NA | NA | NA |
| Byrne *et al*.18 | NA | NA | RCT | NA | NA |
| Chan *et al*.20 | TAF: 38±11TDF: 38±12 | TAF: 371/581TDF: 189/292 | TAF: 41/581TDF: 24/292 | NA | TAF (log10 IU/mL): 7.6±1.34TDF (log10 IU/mL): 7.6±1.41 |
| TDF+ETV vs. TDF | Jeon  *et al*.21 | TDF+ETV: 52.6±9.4TDF: 55.5±13.4 | TDF+ETV: 33/42TDF: 8/12 | NA | Experienced | TDF+ETV (log10 IU/mL): 4.69±1.89TDF (log10 IU/mL): 4.10±2.80 |
| Lim *et al*.23 | TDF+ETV: 52±10TDF: 51±9 | TDF+ETV: 36/45TDF: 32/45 | NA | Experienced | TDF+ETV (log10 IU/mL): 4.69±1.89TDF (log10 IU/mL): 4.10±2.80 |
| Lim *et al*.24 | TDF+ETV: 51 (26-70)TDF: 51 (22-68) | TDF+ETV: 82/97TDF: 74/95 | TDF+ETV: 22/97TDF: 18/95 | Experienced | TDF+ETV (log10 IU/mL): 3.65 (1.98-8.79)TDF (log10 IU/mL): 3.89 (1.78-9.00)  |
| Lok *et al*.25 | TDF: 40 (1.1)TDF+ETV: 39 (1.0) | TDF+ETV: 116/182TDF: 146/197 | NA | Naïve | TDF+ETV (log10 IU/mL): 7.5 (0.10)TDF (log10 IU/mL): 7.5 (0.11) |
| Lu *et al*.35 | TDF+ETV: 40 (26-69)TDF: 40 (19-75) | TDF+ETV: 27/43TDF: 16/25 | NA | Experienced | TDF+ETV (log10 IU/mL): 7.71±1.15 TDF (log10 IU/mL): 6.69±2.03 |
| Wang *et al*.40 | TDF+ETV: 45.0 (23.0-71.0)TDF: 44 (25-67) | TDF+ETV: 59/80TDF: 50/63 | NA | Experienced | TDF+ETV (log10 IU/mL): 3.65(2.68-4.93) TDF (log10 IU/mL): 3.85 (2.84-4.97) |